Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3363288 | 0.85 | — | — | |
| SCHEMBL951792 | 0.79 | CES2 (0.36) | CES2CES1MGLLHDAC8HDAC6 | |
| SCHEMBL1000536 | 0.76 | MGLL (0.39) | CES2CES1NOS2MGLLHDAC8 | |
| SCHEMBL11210860 | 0.76 | CES2 (0.38) | CES2CES1NOS2MGLLHDAC8 | |
| SCHEMBL16876943 | 0.76 | TSHR (0.32) | TSHR | |
| SCHEMBL23547192 | 0.76 | CES2 (0.38) | CES2CES1NOS2MGLLHDAC8 | |
| SCHEMBL11645662 | 0.76 | CES2 (0.32) | CES2CES1NOS2ALDH1A1TSHR | |
| SCHEMBL11211286 | 0.76 | CES2 (0.38) | CES2CES1NOS2MGLLHDAC8 | |
| SCHEMBL8464246 | 0.76 | CES2 (0.38) | CES2CES1NOS2MGLLHDAC8 | |
| SCHEMBL11598841 | 0.74 | CES2 (0.36) | CES2CES1MGLLHDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107266401-A | Cleansing composition | 株式会社新高 | 2017-10-20 | — | — | CN | disclosed |
| CN-105339479-A | Cleaning agent composition | NIITAKA CO LTD | 2016-02-17 | — | — | CN | disclosed |
| CN-104812882-A | Cleaning agent composition | NIITAKA CO LTD | 2015-07-29 | — | — | CN | disclosed |
| CN-104769091-A | NONIONIC SURFACTANT AND METHOD FOR PRODUCING NONIONIC SURFACTANT | NIITAKA CO LTD | 2015-07-08 | — | — | CN | disclosed |
| US-7728022-B2 | (3-phenyl-1-{1-[4-(trifluoromethyl)phenyl]butyl}-4,5,6,7-tetrahydro-1H-indol-7-yl)acetic acid, used for treating diseases associated with the deposition of beta -amyloid peptide in the brain | MERCK SHARP & DOHME LTD. (GB) | 2010-06-01 | — | — | US | disclosed |
| US-7728022-B2 | (3-phenyl-1-{1-[4-(trifluoromethyl)phenyl]butyl}-4,5,6,7-tetrahydro-1H-indol-7-yl)acetic acid, used for treating diseases associated with the deposition of beta -amyloid peptide in the brain | MERCK SHARP & DOHME LTD. (GB) | 2010-06-01 | — | — | US | disclosed |
| US-7728022-B2 | (3-phenyl-1-{1-[4-(trifluoromethyl)phenyl]butyl}-4,5,6,7-tetrahydro-1H-indol-7-yl)acetic acid, used for treating diseases associated with the deposition of beta -amyloid peptide in the brain | MERCK SHARP & DOHME LTD. (GB) | 2010-06-01 | — | — | US | disclosed |
| EP-1748982-B1 | (4, 5, 6, 7-TETRAHYDRO-1-H-INDOL-7-YL) ACETIC ACID DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (GB) | 2009-07-29 | — | — | EP | disclosed |
| EP-1748982-B1 | (4, 5, 6, 7-TETRAHYDRO-1-H-INDOL-7-YL) ACETIC ACID DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (GB) | 2009-07-29 | — | — | EP | disclosed |
| US-20070232678-A1 | (4, 5, 6, 7-Tetrahydro-1-H-Indol-7-Yl) Acetic Acid Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2007-10-04 | — | — | US | disclosed |
| US-20070232678-A1 | (4, 5, 6, 7-Tetrahydro-1-H-Indol-7-Yl) Acetic Acid Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2007-10-04 | — | — | US | disclosed |
| US-20070232678-A1 | (4, 5, 6, 7-Tetrahydro-1-H-Indol-7-Yl) Acetic Acid Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2007-10-04 | — | — | US | disclosed |
| WO-2005108362-A1 | (4, 5, 6, 7-TETRAHYDRO-1-H-INDOL-7-YL) ACETIC ACID DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LIMITED (GB) | 2005-11-17 | — | — | WO | disclosed |
| US-5258400-A | Immunosuppressive compounds for psoriasis | ALLERGAN, INC. (US) | 1993-11-02 | — | — | US | disclosed |
| US-5112853-A | Antiarthritic, calcium channel blockers, immunosuppresive | ALLERGAN, INC. (US) | 1992-05-12 | — | — | US | disclosed |
| EP-0472790-A1 | Asymmetric epoxidation using a chiral hydroperoxide | ARCO Chemical Technology, L.P. (US) | 1992-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232678-A1 | (4, 5, 6, 7-Tetrahydro-1-H-Indol-7-Yl) Acetic Acid Derivatives for Treatment of Alzheimer's Disease | APP, BACE1, CHAT | CES2 2407/4885CES1 1057/4885NOS2 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.